Groundbreaking Trial Targets Typhoid and Paratyphoid A

A novel vaccine trial is underway, aiming to offer protection against both paratyphoid A and typhoid fever. This combined approach could significantly reduce the global burden of these diseases. The study represents a crucial step in safeguarding public health.

A Landmark Moment

The seven-month trial will monitor participants closely throughout its duration. The Serum Institute of India is funding the project, and participants are to receive compensation for their time and travel. The director of the Oxford Vaccine group, Professor Sir Andrew Pollard, is also the Chief Investigator for the study.

“Not only would this be the first licensed vaccine specifically for paratyphoid A, but this could also be the first combined vaccine to be licensed to protect against both paratyphoid and typhoid.”

—Professor Sir Andrew Pollard, Director of the Oxford Vaccine group

Approximately 11 million cases of typhoid fever occur each year, leading to around 116,000 fatalities, according to the World Health Organization (WHO 2024). This underscores the urgency of preventative strategies.

Trial Details

The vaccine under evaluation seeks to induce an immune response that provides protection. The trial is a collaborative effort, designed to assess the safety and efficacy of the new vaccine. If successful, it could be a vital tool in the fight against these diseases.

Professor Pollard believes the vaccine has the potential to substantially lessen the global impact of the illnesses.